Daxor Corp.

Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage and andrology services, such as semen analysis, sperm washing, and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in Oak Ridge, TN.

DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility.   The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.

NEW YORK, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with The Uniformed Services University of the Health Sciences (“USU”), an institution of higher learning within the United States Department of Defense (DoD), and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on behalf of USU’s Battlefield Shock and Organ Support Research Program (BSOS). The partnership includes researching the effectiveness of Daxor’s BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury.

DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES

NEW YORK, July  20, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreements with several institutional investors for the purchase in a registered direct offering of 125,000 shares of its common stock from the Company, and 225,000 shares of its common stock from the Estate of Joseph Feldschuh, at a purchase price of $20.00 per share, for aggregate gross proceeds of $7.0 million. The Company intends to use $2.5 million of the gross proceeds for working capital and other general corporate purposes for the Company. $4.5 million of the gross proceeds would be received by the Estate of Joseph Feldschuh.

Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering

Enrollment Commences Using the BVA-100  ®   Diagnostic Blood Test

DAXOR ANNOUNCES PROSPECTIVE RANDOMIZED CONTROL TRIAL AT DUKE UNIVERSITY MEDICAL CENTER TO GUIDE VOLUME TREATMENT IN HEART FAILURE PATIENTS

COVID-19 Investigation Commences at NYU Langone Health with Daxor’s Blood Volume Analysis Technology

Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100® Study in Hospitalized Patients With COVID-19

NEW YORK, July  08, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, has signed a new distribution agreement with American Medical Depot “AMD,” one of the nation’s largest and diversified government healthcare distributors. As part of the agreement, the two parties are set to provide Daxor’s BVA-100 diagnostic blood test (Blood Volume Analysis) “BVA,” to government facilities across the United States, driving forward the use of BVA to help guide precise, individualized volume management in a wide variety of medical conditions including heart failure and COVID-19 related symptoms.

DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH AMERICAN MEDICAL DEPOT GOVERNMENT DISTRIBUTOR

NEW YORK, June  30, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the appointments of Dr. Henry D. Cremisi and Joy Goudie, Esq. to the Company's Board of Directors, effective June 29, 2020. Ms. Goudie is replacing Berne Saxe, Esq. after having served as a Board Member for 12 years.

Daxor Corporation Announces Appointment of Henry D. Cremisi, MD, FACP and Joy Goudie, Esq.

NEW YORK, May  26, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that its CEO, Michael Feldschuh, will be a panelist in Maxim Group and M-Vest’s COVID-19 Virtual Series on May 27, 2020.

Daxor Corporation, CEO Michael Feldschuh to Participate in Maxim Group’s  COVID-19 Virtual Conference on May 27, 2020

NEW YORK, May  22, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that blood volume outcome data has been published in the scientific journal, Circulation, utilizing Daxor’s BVA-100 blood volume measurement device to determine the primary endpoint of the study, Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects, at Yale University. The results further validate the important role of changes in blood volume and plasma volume status and its contribution to the superior long-term heart failure (HF) outcomes.

Daxor’s BVA-100® Published in Novel Study in American Heart Association Journal - Circulation

New York, April  23, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the United States Department of Defense (DOD) has awarded the Company a $1.1 million contract for the development and deployment of a small, portable, highly accurate, battery-powered Blood Volume Analyzer.

Daxor Awarded $1.1 Million Contract from United States Department of Defense (DOD) for Rapid Portable Blood Volume Analyzer

New Clinical Protocol for Volume-Guided Therapy Helps Combat Coronavirus

Daxor Corporation’s BVA-100® Test Used to Guide Treatment In COVID-19 Patient

NEW YORK, March  09, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Air Force (USAF) has awarded Daxor a contract to define specifications to adapt blood volume analysis technology to meet the needs of USAF.

Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for U.S. Air Force Needs

NEW YORK, March  06, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE American: DXR)  (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has closed its previously announced registered direct offering priced at-the-market of 140,352 shares of its common stock at a price of $14.25 per share, for aggregate gross proceeds of approximately $2.0 million. The Company intends to use the net proceeds for working capital and other general corporate purposes.

Daxor Corporation Announces Closing of $2.0 Million Registered Direct Offering Priced At-The-Market

NEW YORK, March  03, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 140,352 shares of its common stock at a price of $14.25 per share, for aggregate gross proceeds of approximately $2.0 million, in a registered direct offering priced at-the-market. The Company intends to use the net proceeds for working capital and other general corporate purposes.

Daxor Corporation Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market

NEW YORK, March  02, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces active engagement with both hospitals and government agencies in the military and civilian sectors regarding the use of its technology to help guide fluid management of critically ill patients with COVID-19.

Daxor Corporation Announces Engagement with Hospitals and Government for Use of the Blood Volume Analyzer (BVA-100®) to Stem COVID-19 Deaths

NEW YORK, March  02, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2019.

DAXOR CORPORATION ANNOUNCES RISE IN KIT SALES AND FILES FORM N-CSR FOR 2019

NEW YORK, Feb.  20, 2020  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new research from the University of Hawaii John A. Burns School of Medicine further demonstrates the clinical superiority of accurate and direct quantification of intravascular blood volume in critically ill patients compared with ultrasound measurement. The new study was presented during the 49th Annual Society of Critical Care Medicine Congress in Orlando, Fla.

New Research Further Demonstrates Clinical Superiority of Daxor Corporation’s Blood Volume Analyzer (BVA-100®) in Critical Care

New Data Scheduled for Presentation on Daxor’s BVA-100®

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th Congress

NEW YORK, Nov.  21, 2019  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from The Yale University School of Medicine that was presented on November 16th at the American Heart Association Scientific Sessions in Philadelphia, PA.

Novel Study from Yale University Utilizes Daxor’s Blood Volume Analyzer (BVA-100®) to Uncover Important Mechanism for Drug Empagliflozin

NEW YORK, Nov.  12, 2019  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the American Heart Association Scientific Sessions (AHA) at the Philadelphia Convention Center in Philadelphia, PA from November 16-18th, 2019.

Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2019

New York, N. Y., Oct.  10, 2019  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced that Michael Feldschuh, Chief Executive Officer of Daxor, will be a featured presenter at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas at the Hilton Austin on Tuesday, October 15th at 1:30 PM (CT). Mr. Feldschuh will provide an overview of the Company’s business model and growth strategy and will be available for one-on-one meetings.

Daxor to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 1:30 PM Central Time

NEW YORK, Sept.  24, 2019  (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data demonstrating the clinical utility of the BVA-100 test in hypertensive patients published in the Journal of Cardiovascular Translational Research from Duke University Medical Center in Durham, NC. 

News for Daxor Corp. Stock (DXR)